Atara Biotherapeutics receives FDA clinical hold on EBVALLO and ATA3219 programs

Atara Biotherapeutics, Inc.

FDA clinical hold on EBVALLO and ATA3219 studies due to GMP compliance issues at third-party manufacturer.
New patient enrollment paused; currently enrolled patients who may benefit can continue treatment.
Clinical hold linked to inadequately addressed GMP issues from Jan 16 CRL for EBVALLO.
Atara's second manufacturer FDB in Thousand Oaks unaffected; remains part of long-term strategy.
FDA committed to working expeditiously with Atara to resolve clinical hold.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.